Edition:
India

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

15.70USD
18 May 2018
Change (% chg)

$-0.37 (-2.30%)
Prev Close
$16.07
Open
$16.08
Day's High
$16.08
Day's Low
$15.60
Volume
418,259
Avg. Vol
774,198
52-wk High
$49.08
52-wk Low
$11.66

Latest Key Developments (Source: Significant Developments)

Mallinckrodt Announces $300 Million Debt Repayment
Tuesday, 17 Apr 2018 

April 16 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT PLC ANNOUNCES $300 MILLION DEBT REPAYMENT.MALLINCKRODT PLC - COMPANY REPAYS DEBT MATURING APRIL 2018 WITH CASH ON HAND.MALLINCKRODT PLC - DEBT WAS ISSUED BY MALLINCKRODT INTERNATIONAL FINANCE SA IN 2013 IN PREPARATION FOR COMPANY'S SPIN-OFF FROM ITS FORMER PARENT.  Full Article

Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Mallinckrodt Plc :MALLINCKRODT WILL SELL RECOTHROM® AND PREVELEAK® TO BAXTER.MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS.MALLINCKRODT PLC - WILL RETAIN RAPLIXA FOR TOPICAL USE AND IS EVALUATING STRATEGIC OPTIONS FOR THIS PRODUCT.MALLINCKRODT - ‍ SALE IS ANTICIPATED TO DILUTE CO'S ADJUSTED EARNINGS PER SHARE BY $0.10 TO $0.15 IN 2018, WHICH WILL BE OFFSET BY SHARES REPURCHASED DURING Q4 2017​.MALLINCKRODT PLC - COMPANY WILL DISCONTINUE MARKETING OF RAPLIXA UPON CLOSE OF BAXTER TRANSACTION.MALLINCKRODT PLC - PROCEEDS FROM SALE WILL BE USED BY COMPANY TOWARD PAYING DOWN DEBT.MALLINCKRODT PLC - ‍WRITE-OFF FOR RAPLIXA​ WILL BE REPORTED FOR Q4 2017.  Full Article

Baxter To Acquire Recothrom, Preveleak For Upfront Payment Of About $153 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES AGREEMENT TO BROADEN PORTFOLIO OF INNOVATIVE SURGICAL PRODUCTS.BAXTER INTERNATIONAL - TO ACQUIRE RECOTHROM AND PREVELEAK FOR UPFRONT PAYMENT OF ABOUT $153 MILLION AND POTENTIAL CONTINGENT PAYMENTS IN FUTURE.BAXTER INTERNATIONAL - UPON CLOSING, DEAL EXPECTED TO BE MODESTLY ACCRETIVE TO BAXTER'S 2018 ADJUSTED EPS & INCREASINGLY ACCRETIVE THEREAFTER.BAXTER INTERNATIONAL - ‍PROPOSED DEAL INCLUDES TWO HEMOSTAT & SEALANT PRODUCTS, INCLUDING STAND-ALONE RECOMBINANT THROMBIN, SURGICAL SEALANT​.  Full Article

Mallinckrodt Unit Borrowed $900 Mln Under Revolving Credit Facility
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT PLC SAYS ON DEC 29 UNIT OF CO BORROWED $900 MILLION AS A REVOLVING LOAN UNDER THE REVOLVING CREDIT FACILITY -SEC FILING.MALLINCKRODT PLC - PURSUANT TO TERMS OF CREDIT AGREEMENT, REVOLVING LOAN MATURES ON FEB 28 2022.  Full Article

Mallinckrodt To Buy Sucampo Pharmaceuticals For About $1.2 Bln
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT TO ACQUIRE SUCAMPO PHARMACEUTICALS FOR APPROXIMATELY $1.2 BILLION.MALLINCKRODT - ‍TRANSACTION WAS APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​ .MALLINCKRODT PLC - MALLINCKRODT TO COMMENCE CASH TENDER OFFER FOR $18.00 PER SHARE, WITH SUPPORT FROM KEY SUCAMPO SHAREHOLDERS.MALLINCKRODT SAYS EXPECTS ACCRETION TO 2018 ADJUSTED DILUTED EARNINGS PER SHARE OF AT LEAST $0.30 AS RESULTS OF DEAL.MALLINCKRODT - DEAL EXPECTED TO BE FUNDED THROUGH BORROWINGS UNDER CO'S EXISTING REVOLVING CREDIT FACILITY, NEW SECURED TERM LOAN FACILITY, CASH ON HAND.MALLINCKRODT PLC - FOLLOWING DEAL, CO INTENDS TO UTILIZE "SIGNIFICANT" CASH GENERATION TO FOCUS ON REDUCING OUTSTANDING DEBT OVER TIME.MALLINCKRODT SAYS EXPECTS ACCRETION TO 2018 ADJUSTED DILUTED EPS OF AT LEAST $0.30; AT LEAST DOUBLE THAT IN 2019, ASSUMING DEAL CLOSES IN Q1 2018.  Full Article

Mallinckrodt Says TCJA Is Expected To Have A Neutral To Slightly Positive Impact On Adj Tax Expense Of Co
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT PLC SAYS TCJA IS EXPECTED TO HAVE A NEUTRAL TO SLIGHTLY POSITIVE IMPACT ON NON-GAAP ADJUSTED TAX EXPENSE OF CO - SEC FILING.MALLINCKRODT - ASSUMING TCJA IS ENACTED INTO LAW, ESTIMATE TCJA WILL RESULT IN DEFERRED TAX BENEFIT OF $450 MILLION-$500 MILLION TO CO.MALLINCKRODT - UNDER TCJA, CO'S INTEREST EXPENSE DEDUCTION IN U.S. TO BE LIMITED TO ABOUT 50% OF EBITDA OF U.S. SUBSIDIARIES THROUGH SEPTEMBER 28, 2018.MALLINCKRODT- UNDER TCJA,INTEREST EXPENSE DEDUCTION IN U.S. EXPECTED TO BE LIMITED TO ABOUT 30% OF EBITDA OF U.S. SUBSIDIARIES THROUGH DEC. 31, 2021.  Full Article

James Flynn reports 6.07 pct passive stake in Mallinckrodt
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Mallinckrodt Plc :James Flynn reports 6.07 percent passive stake in mallinckrodt plc ‍​as of November 7 - sec filing.  Full Article

Mallinckrodt Q3 earnings per share $0.66
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Mallinckrodt Plc : :Mallinckrodt Plc reports earnings results for third quarter of fiscal 2017.Q3 sales $793.9 million.Q3 GAAP earnings per share $0.66 from continuing operations.Mallinckrodt Plc - ‍net sales were $793.9 million in Q3, down 10.5%, or 10.6% on a constant-currency basis​.Q3 earnings per share view $1.81, revenue view $811.9 million -- Thomson Reuters I/B/E/S.Mallinckrodt-On completing internal legal entity reorganization in Q4,expects to record one-time reduction to deferred income taxes in excess of $800 million​.Mallinckrodt Plc - qtrly ‍adjusted diluted earnings per share of $1.97​.  Full Article

Mallinckrodt to acquire Ocera Therapeutics and OCR-002, its proprietary therapy
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Mallinckrodt Plc :Mallinckrodt to acquire Ocera Therapeutics and OCR-002, its proprietary therapy in development for treatment of hepatic encephalopathy.Mallinckrodt Plc - ‍Mallinckrodt to commence cash tender offer to purchase ocera therapeutics for $1.52 per share, plus contingent value right​.Mallinckrodt Plc - ‍Assuming expected 2017 deal close, expects dilution from deal to adjusted EPS of about $0.25 to $0.35 annually beginning in 2018​.Mallinckrodt Plc - Expects dilution from acquisition to adjusted diluted earnings per share by $0.25 to $0.35 annually beginning in 2018​.Mallinckrodt - Deal includes ‍contingent value right in cash up to $2.58/share based on successful completion of some development and sales milestones​.  Full Article

Mallinckrodt to conduct Phase 4 trial of H.P. Acthar Gel
Monday, 9 Oct 2017 

Oct 9 (Reuters) - Mallinckrodt PLC :Mallinckrodt will conduct Phase 4 trial of H.P. Acthar® Gel (repository corticotropin injection) for symptomatic sarcoidosis.Mallinckrodt PLC - ‍enrollment of first subjects expected in early 2018 for Phase 4 trial of H.P. Acthar Gel​.  Full Article